Amylyx Pharmaceuticals (AMLX) Net Margin (2021 - 2024)

Amylyx Pharmaceuticals' Net Margin history runs 4 years deep, the most recent figure standing at 4011.01% for Q4 2024.

• On a quarterly basis, Net Margin fell 401349.0% year-over-year to 4011.01% in Q4 2024; TTM through Sep 2025 was 13557.55%, a 1368926.0% increase from a year earlier, with the FY2024 full-year figure at 273.1%, down 28550.0% from the prior year.
• Net Margin advanced to 4011.01% in Q4 2024 per AMLX's latest filing, from 17476.92% in the prior quarter.
• Across five years, Net Margin topped out at 22.47% in Q2 2023 and bottomed at 17476.92% in Q3 2024.
• The 4-year median for Net Margin is 200.17% (2022), against an average of 4780.24%.
• Across the five-year window, Net Margin jumped 1560179 bps in 2023 and plunged 1749727 bps in 2024, its largest moves.
• Year by year, Net Margin stood at 8120.0% in 2021, then surged by 98 bps to 200.17% in 2022, then jumped by 101 bps to 2.49% in 2023, then slumped by 161386 bps to 4011.01% in 2024.
• Per Business Quant, the three latest AMLX Net Margin figures stand at 4011.01% (Q4 2024), 17476.92% (Q3 2024), and 7106.55% (Q2 2024).